There is a Computerized Neuropsychological evaluation known as Qb Test, that can be used as an adjunct in Diagnosis and Treatment of ADHD.
QbTest (K040894) was cleared by the FDA in 2004 to aid in the clinical assessment of ADHD in children aged 6-12 years old. An updated version of QbTest (K122149) was cleared October 17, 2012 and expanded the indication for use to include the clinical assessment of ADHD In adolescents and adults (aged 12-60). In April 2014, QbTest was cleared to aid in the treatment interventions and follow up for ages 6-60. Cleared as a Class II device by the FDA, QbTest has demonstrated strong and sufficient evidence for positively identify an ADHD individual from the non ADHD cohort as well as identifying individuals as not having ADHD. In short, the testing with interpretation by a trained professional has a very high sensitivity and specificity and strong balance between the two.
QbTest is today the only ADHD test that is cleared and registered by regulatory authorities in both the US as well as in Europe. More than 170,000 patients in 10 countries have performed a QbTest as a part of their assessment and/or treatment evaluation.
Benefits of using QbTest
At the present, ADHD is primarily identified on the basis of self-reports, parent, teacher and clinician ratings of the presence or absence of a list of symptoms and judgments about functional impairment1. Behavioral ratings are problematic because they are subjective in nature with potential biases and individual inconsistency in perceived meaning of items. This results in poor inter-rater reliability, with parents generally less accurate than teachers when compared to objective test
QbTest has high clinical validity and has shown significant results in several publications and audit studies (see Clinical Documentation included). The test also has several other initial advantages:
- The test is time efficient for the patient and the data is available to the physician in real time allowing for diagnosis and treatment to begin on the same day. Getting the diagnosis right at the beginning leads to fewer visits for evaluation
- The test is non-invasive and non-language based. It is designed to reduce the impact of confounding factors, such as problems differentiating from left to right, dyslexia and underlying anxiety. Patients with dyslexia and anxiety are commonly misdiagnosed as having ADHD because there is significant symptom overlap. To confound the issue further, both dyslexia and anxiety are common ADHD comorbidities, existing side by side with the neurology of ADHD.
1 Taylor, E., DOpfner, M.,Sergent, J.,Asherson, P.,Banaschewski, T.,Buitelaar,J.,Coghill,D.,Danckaerts,M.,Rothenberger,A.,Sonuga-Barke,E.,Steinhausen,H.,&Zuddas,A. (2004).European clinical guidelines for hyperkinetic disorder – first upgrade. Eurpean Child & Adolecent Psychiatry, 13(suppl 1), 17-130
To read more about QB Testing please visit the company website at www.qbtech.com.